Alzheimer's vaccine trial a success

Friday, 08 June 2012

Alzheimer's disease is a complex neurological dementia disease that is the cause of much human suffering and a great cost to society. According to the World Health Organisation, dementia is the fastest growing global health epidemic of our age. The prevailing hypothesis about its cause involves APP (amyloid precursor protein), a protein that resides in the outer membrane of nerve cells and that, instead of being broken down, form a harmful substance called beta-amyloid, which accumulates as plaques and kills brain cells.

There is currently no cure for Alzheimer's disease, and the medicines in use can only mitigate the symptoms. In the hunt for a cure, scientists are following several avenues of attack, of which vaccination is currently the most popular. The first human vaccination study, which was done almost a decade ago, revealed too many adverse reactions and was discontinued. The vaccine used in that study activated certain white blood cells (T cells), which started to attack the body's own brain tissue.

The new treatment, which is presented in Lancet Neurology, involves active immunisation, using a type of vaccine designed to trigger the body's immune defence against beta-amyloid. In this second clinical trial on humans, the vaccine was modified to affect only the harmful beta-amyloid. The researchers found that 80 per cent of the patients involved in the trials developed their own protective antibodies against beta-amyloid without suffering any side-effects over the three years of the study. The researchers believe that this suggests that the CAD106 vaccine is a tolerable treatment for patients with mild to moderate Alzheimer's. Larger trials must now be conducted to confirm the CAD106 vaccine's efficacy.

The study was carried out by Professor Bengt Winblad at Karolinska Institutet's Alzheimer's Disease Research Centre in Huddinge and leading neurologists in the Swedish Brain Power network: consultant Niels Andreasen from Karolinska University Hospital, Huddinge; Professor Lennart Minthon from the MAS University Hospital, Malmö; and Professor Kaj Blennow from the Sahlgrenska Academy, Gothenburg. The study was financed by Swiss pharmaceutical company Novartis.

Bengt Winblad, Niels Andreasen, Lennart Minthon, Annette Floesser, Georges Imbert, Thomas Dumortier, R Paul Maguire, Kaj Blennow, Joens Lundmark, Matthias Staufenbiel, Jean-Marc Orgogozo & Ana Graf
Safety, tolerability, and antibody response of active A²immunotherapy with CAD106 in patients with Alzheimers disease: randomised, double-blind, placebo-controlled, first-in-human study Lancet Neurology, online first 6 June 2012, doi:10.1016/S1474-4422(12)70140-0